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Case presentation
A 53-year-old man was referred to the Royal Melbourne Hospital for
evaluation and treatment of episcleritis. He was a widower living in a
country town and, apart from an appendectomy, had been in excellent
health. Twelve years before the admission, rheumatoid arthritis com-
menced in his hands and wrists with morning stiffness, swelling, and
pain. Initially, treatment with aspirin produced relief, but the disease
progressed to the shoulders, elbows, knees, hips, and neck. Although
ibuprofen ameliorated his symptoms, it produced indigestion. Gastros-
copy revealed a duodenal ulcer. He was treated with cimetidine, and
sulindac was substituted for ibuprofen. His blood pressure at that time
was 140/80 to 150/85 mm Hg.
Four years prior to admission, he developed a cataract in his right
eye. Blood pressure was 140/85 mm Hg. Six months prior to admission,
his right eye became red and painful; episcleritis was diagnosed. Blood
pressure was 145/90 mm Hg. He was treated initially with hydrocorti-
sone eye drops, but pain and redness persisted and he was given
prednisolone, 40 mg orally daily. Two weeks later his eye was much
improved but the blood pressure had risen to 160/95 mm Hg and he had
glucosuria. Because the fasting blood glucose level was elevated, a
diabetic diet was prescribed. The prednisolone dose was reduced to 20
mg/day. Four weeks later, severe symptoms and signs of episcleritis
became manifest. The blood pressure was 160/100 mm Hg and the blood
glucose remained elevated. Prednisolone was increased to 40 mg daily;
glibenclamide, 5 mg per day, and verapamil, 40 mg four times daily,
were given. The blood pressure continued to increase, and 2 months
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later was 165/105 mm Hg while he was taking verapamil, 80 mg four
times a day.
On admission to The Royal Melbourne Hospital, he complained of
pain and stiffness in many joints and minimal discomfort in his right eye.
He had a family history of maturity-onset diabetes (in his father and
maternal grandfather). Another brother and 5 sisters all were well. His
wife had died 5 years previously.
Physical examination revealed a middle-aged white male with a red
right eye. Episcleral vessels were diffusely injected and the episclera
was thickened inferiorly. Visual acuity in the left eye was 6/5, but only
light and dark could be distinguished in the right eye. Typical changes
of rheumatoid arthritis affected his hands, with tenderness and synovial
swelling of metacarpal-phalangeal and proximal interphalangeal joints.
There were nodules over both elbows and some tenderness was present
on movement of shoulders and knees. Blood pressure was 160/100 mm
Hg. The rest of the examination, including urinalysis, was unremark-
able.
The laboratory findings were: hematocrit, 48.4%; erythrocyte sedi-
mentation rate, 31 mm/hr; positive Rose Waaler and latex tests;
negative DNA binding; plasma sodium, 135 mmol/liter; potassium, 3.9
mmol/liter; chloride, 98 mmol/liter; bicarbonate, 27 mmol/liter; creati-
nine, 0.08 mol/liter (0.9 mg/dl); urate, 0.31 mmol/liter (5.2 mg/dl);
albumin, 35 g/liter (3.5 g/dl), and fasting blood glucose, 5.7 mmol/liter
(103 mg/dl). Full blood examination (hemoglobin, differential white cell,
and platelet count), liver function tests, serum lipids, electrocardio-
gram, chest x-ray, and urine microscopy all were normal. Plasma renin
concentration was 20 dU/ml (normal ambulant range, 11—75 .dU/ml).
The steroid therapy was reduced gradually. His symptoms of arthritis
flared but were controlled with naproxen suppositories, and adminis-
tration of intramuscular gold was commenced. Immunosuppressive
therapy was considered for the episcleritis but was withheld while the
disease remained controlled. He currently takes 15 mg of prednisolone
daily. Glibenclamide has been withdrawn. The blood pressure is 150/95
mm Hg with the patient taking 100 mg of metoprolol daily.
Discussion
DR. JUDITH A. WHITWORTH (Assistant Director, Depart-
ment of Nephrology, The Royal Melbourne Hospital; and
Research Associate, Howard Florey Institute of Experimental
Physiology and Medicine, University of Melbourne, Victoria,
Australia): Hypertension is common in patients receiving glu-
cocorticoid therapy. In considering the nature and extent of the
problem of glucocorticoid-induced hypertension, I will briefly
discuss the classification of adrenocortical steroid hormones,
their mechanisms of action, and the history of development of
synthetic glucocorticoids. I will spend most of my time discuss-
ing the association of hypertension with synthetic steroid ad-
ministration, the hypertension of Cushing's syndrome, experi-
mental studies of glucocorticoid-induced hypertension in hu-
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Physiology of steroid hormones
Class(fication of adrenocortical steroid hormones
Adrenocortical steroid hormones are arbitrarily classified
into two major categories, glucocorticoid and mineralocor-
ticoid. Those with glucocorticoid activity have ubiquitous ac-
tions, affecting virtually every body tissue. Glucocorticoids
affect intermediary metabolism, immunity, and inflammation,
whereas mineralocorticoids are vital in salt and water balance.
Biologic potency in these broad areas can be classified relative
to other hormones. The distinction between glucocorticoid and
mineralocorticoid effects is often one of degree, however, and
predominantly depends on the dose of steroid. The major
naturally occurring glucocorticoid in humans, cortisol, has
some mineralocorticoid activity at high physiologic concentra-
tions, whereas aldosterone, the major mineralocorticoid, is
present in much lower concentrations in plasma, at which it has
no effective glucocorticoid activity.
The demonstration of steroid receptors has led to a more
sophisticated classification of steroid hormones based on in-
vitro receptor affinity [1, 2]. Measurement of type-lI glucocor-
ticoid receptor binding utilizes 3H-dexamethasone, a synthetic
steroid that shows negligible binding to cortisol-binding globulin
(CBG), as ligand, rather than the naturally occurring cortisol.
Bartter suggested that as neither mineralocorticoids nor gluco-
corticoids can be defined rigorously, the terms might have
outlived their usefulness [3]. It is more accurate to think of
steroids as having glucocorticoid activity, with or without other
activities, rather than as these agents being glucocorticoid
hormones.
Mechanisms of action
After transport to cell surfaces of target cells by binding
proteins (see following), steroid hormones move through the
plasma membranes. Receptor proteins are found in the cyto-
solic fraction, although for some steroids, such as estrogen, the
receptor is in the nucleus [4]. Interaction of hormone-receptor
complexes with the genome via a chromosomal acceptor in the
nucleus leads to transcription, translation, and protein synthe-
sis. Evidence suggests that the number of glucocorticoid recep-
tors is the limiting factor in hormone response [51.Steroids also
can have non-genomic actions. Steroid effects of rapid onset
and short duration are possibly too fast to be explained by a
genomic mechanism [6], for example, actions on the central
nervous system.
In humans, most of the circulating cortisol is bound by CBG
or albumin. Also called transcortin, CBG is an a2 globulin [7];
it binds various other steroids (such as cortisone, corticoster-
one, deoxycorticosterone, 1 1—deoxycortisol, progesterone, and
prednisolone) in addition to cortisol, but the binding affinities or
plasma concentrations of these steroids are much lower than
are those of cortisol, with the exception of progesterone in late
pregnancy. Under basal conditions, the ratio of CBG bound,
albumin-bound, and free cortisol is 7:2:1. Binding to albumin
increases as CBG binding capacity is exceeded (approximately
25 g/l00 ml). The metabolic clearance rate of cortisol in
humans is approximately 10 liters/hour [8], the production rate




Fig. 1. Trivial name, structure, and relative potency of some naturally
occurring and synthetic steroids.
Synthetic steroids
Adrenocortical steroid hormones were first synthesized 50
years ago [10]. Hench pioneered the clinical work on the
antiinflammatory effects of cortisone [11]. The dramatic re-
sponse in rheumatic disease was accompanied by numerous
side effects, so a search began for safer compounds [12].
Most synthetic steroids were developed by partial synthesis
from related natural steroids. Figure 1 shows the structure and
relative potency of some naturally occurring and synthetic
steroids. In the l950s, many analogues of 11—oxygenated ste-
roids were synthesized, several of which were more potent than
cortisol in terms of glucocorticoid activity [13—16]; i' unsatu-
ration increased in-vivo glucocorticoid potency, substitution of
a chlorine or fluorine atom in the a-configuration at position 9
greatly enhanced both in-vivo mineralocorticoid and glucocor-
ticoid activities, and the combination of unsaturation and
9a-fluoro substitution synergistically increased glucocorticoid
activity. Fried and Sabo found that 9 halogenated cortisols
(such as 9a fluorocortisol) were more potent than were the
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parent form [13], and Hertzog and coworkers found that pred-
nisone and prednisolone, which differed from cortisone and
cortisol by virtue of an additional double bond in ring A, were
more active and less likely to cause salt retention [15].
The clinical effects of glucocorticoids—suppression of in-
flammation and immunity—have been widely utilized in the
treatment of vasculitis, arthritis, skin diseases, malignancy, and
multisystem disease. In nephrologic practice they are used
extensively in management of primary nephrotic syndrome due
to minimal-lesion and membranous nephropathy, in rapidly
progressive glomerulonephritis and secondary glomerulone-
phritis (systemic lupus erythematosus, polyarteritis, Goodpas-
ture's syndrome), and in transplantation.
Hypertension as a consequence of glucocorticoid
administration
Soon after the introduction of pharmacologic glucocorticoid
therapy, hypertension was noted as a complication of treatment
with cortisone [17—19]. Corticosteroid therapy probably con-
tributes to the hypertension seen in renal allograft recipients
[20], and conversion from daily to alternate-day steroids re-
duces blood pressure in some patients [21].
Hypertension occurs in 20% of patients with iatrogenic
Cushing's syndrome [22, 23], compared with 80% of patients
with the naturally occurring disease. Some have suggested that
this lower incidence of high blood pressure with exogenous
glucocorticoids reflects the use of cortisol derivatives, which
have greater antiinflammatory and lesser salt-retaining proper-
ties than does the natural hormone [24]. However, as I will
discuss later, whether steroids exert their effects on blood
pressure by classic mineralocorticoid or glucocorticoid actions
is debatable [25]. Impaired renal function increases the inci-
dence of hypertension during cortisone therapy [26].
Hypertension in Cushing's syndrome
Cushing's syndrome, defined as the clinical features associ-
ated with prolonged exposure to elevated glucocorticoid blood
levels, encompasses a number of clinical states. The syndrome
can be divided into ACTH-dependent and adrenal forms. The
ACTH-dependent form comprises pituitary ACTH excess
(Cushing's disease), which accounts for some two-thirds of
cases; production of ectopic ACTH (or pro-opiomelanocortin
[POMC] or corticotropin releasing factor) by endocrine tumors
(for example, medullary carcinoma of the thyroid) or nonendo-
crime tumors (such as oat cell tumor of the lung); and exogenous
ACTH administration (for example, in the management of
infantile spasms). The adrenal form comprises adrenal adenoma
and carcinoma and exogenous glucocorticoid administration.
Cushing's syndrome is the cause of hypertension in approx-
imately one in 300 to 400 hypertensives. Among patients with
Cushing's syndrome, hypertension is very common, affecting
some 80% of patients [27—29]. Greminger and colleagues re-
ported that 64% of patients with Cushing's disease were hyper-
tensive (average blood pressure, 158/100 mm Hg), compared
with 83% of patients with adenoma (average blood pressure,
164/100 mm Hg) and 100% with carcinoma (average blood
pressure, 184/114mm Hg) [27]. Ross et al found hypertension in
87% of patients with hyperplasia and in all of 15 patients with
adrenal tumors [29]. Welbourn and coworkers found that 93%
of patients were hypertensive but that the incidence and sever-
ity of hypertension were unrelated to gender, the nature of the
underlying lesion, or the duration or severity of symptoms.
Blood pressure was raised 43/29 mm Hg compared with age-
and sex-matched normal control subjects. Forty percent of the
patients had cardiovascular complications [30]. The proportion
of patients with ectopic ACTH production who are hyperten-
sive is usually lower than in other forms of Cushing's syndrome
[31]. This might reflect the relatively short duration of the
disease, a different pattern of steroid production, or the under-
lying malignancy. Cushing's syndrome is an aggressive disease
with a 50% 5-year mortality in untreated patients [32]. Even
with a permanent biochemical remission, mortality is still 4
times that of the general population [33], largely because of
cardiovascular disease.
A reversible "pseudo-Cushing's syndrome" occurs in asso-
ciation with alcohol abuse [34], and these patients are usually
hypertensive. Alcohol stimulates POMC expression, and it is
possible that the well-documented association between hyper-
tension and alcohol consumption [35] might relate to overactiv-
ity of the hypothalamic-pituitary adrenal axis.
Models
Hypertension in experimental studies in humans
Our studies have shown that short-term ACTH administra-
tion increases blood pressure in normal and hypertensive
adults, but not in patients with Addison's disease [36]. Admin-
istration of ACTH increased cardiac index and plasma volume
[37], but did not change peripheral resistance. Plasma renin
substrate rose, plasma renin concentration fell [36], and urinary
kallikrein activity increased [38].
To determine which of the one or more steroids were
responsible for the hypertensive effects of ACTH, cortisol or
deoxycorticosterone was infused at rates that produced blood
concentrations of steroid appropriate for conditions of ACTH
stimulation [39]. Cortisol infusion reproduced the blood pres-
sure and metabolic effects of ACTH administration, whereas
deoxycorticosterone infusion did not. It thus appears that the
rise in blood pressure that occurs with short-term ACTH
administration in humans is due to the increased secretion of
cortisol. Whether these observations are relevant to Cushing's
disease is speculative, because patients with Cushing's disease
often have ACTH concentrations that are normal or only mildly
elevated [40].
We infused cortisol intravenously at a rate of 6 to 8 mg/hour
for 5 days in 7 subjects [39] and in separate studies gave oral
hydrocortisone, 50 mg every 6 hours, to 6 other subjects for 5
days [41]. In both sets of experiments daily electrolyte intake
was constant: 100 mmol sodium and 100 mmol potassium for
the intravenous study; 150 mmol sodium and 70 mmol potas-
sium for the oral study. With constant infusion, plasma cortisol
concentration doubled; with oral administration, plasma corti-
sol concentration rose to a similar extent at 0900 hours but was
not maintained throughout the day, and at 2400 hours was
similar to control values. This probably reflects the variable
bioavailability of the oral preparation [42] and might explain the




Cortisol infusion increased supine systolic blood pressure
(SBP) 21 mm Hg (Fig. 2). Blood pressure rose in all 7 subjects
and was high in both morning and afternoon readings and with
supine and standing readings. No changes were apparent in
mean or diastolic pressures or pulse rate. Oral administration
increased supine SBP only 5 mm Hg. Standing systolic pressure
also was increased. No changes were detected in mean or
diastolic pressure, nor were consistent changes noted in pulse
rate. Cardiac output, as assessed by maximum aortic velocity
determined by echocardiography, rose from 97 5 to 113 5
ml/sec.
Metabolic and hormonal effects
With cortisol infusion (Fig. 2), plasma sodium increased,
plasma potassium fell, and blood glucose was markedly in-
creased as anticipated. Plasma urea and creatinine clearance
increased. Body weight increased and hemoglobin and hemato-
crit fell, accompanied by cosinopenia and lymphocytosis; the
total leukocyte count was increased. Cortisol withdrawal
prompted increases in fluid intake and urine output as well as a
diuresis. Initial urinary sodium retention was followed by a
large natriuresis and a reduction in urinary potassium excretion
when the infusion was stopped.
Hypernatremia, hypokalemia, and initial sodium retention
are mineralocorticoid effects and presumably reflect the binding
of cortisol to the type-I (mineralocorticoid) receptor. Increases
in water drinking and urine output and a rise in blood glucose
are typical glucocorticoid effects (binding to type-I! receptors).
With oral cortisol, changes were similar to those seen in the
intravenous infusion. When oral hydrocortisone was adminis-
tered, plasma volume increased by approximately 800 ml, with
an increase in exchangeable sodium of some 340 mmol, which
was accounted for by cumulative urinary sodium retention and
a 3 liter expansion of extracellular fluid volume [41]. By the fifth
day of hydrocortisone treatment, sodium output was equivalent
to intake.
With cortisol infusion, plasma renin concentration (PRC) fell;
2 days after cessation of infusion the PRC was still low. Inactive
renin was unchanged and renin substrate was increased (Fig. 2).
With oral steroid administration, similar changes were seen in
PRC, and angiotensin II concentrations decreased. The rise in
renin substrate is a classic glucocorticoid effect. Renin concen-
tration was still suppressed 48 hours after cessation of infusion.
Thus some other factor, apart from increases in volume and
blood pressure, might be contributing to the suppression. The
renin-angiotensin system does not appear to play a major role in
the hypertension of Cushing's syndrome. Administration of the
angiotensin II antagonist saralasin had no effect on blood
pressure in patients with Cushing's syndrome [43], and in
another study, the angiotensin converting enzyme inhibitor
captopril produced a reduction in pressure in some patients
with high renin but had little or no effect on patients with normal
or low renin [44]. In our study with oral hydrocortisone, plasma
adrenaline concentrations were essentially unchanged, but
plasma noradrenaline fell, suggesting a decrease in sympathetic
activity. Plasma vasopressin showed little change [45], but
atrial natriuretic peptide concentrations increased markedly
[411.
Renal function
The role of adrenal steroid hormones in maintaining normal
renal function is well recognized [46]. In Addison's disease,
with glucocorticoid and mineralocorticoid deficiency, both
glomerular filtration rate (GFR) and renal blood flow (RBF) are
low. Cortisol appears to be essential for the maintenance of
GFR and RBF independent of changes in volume or electrolyte
status. Glucocorticoid administration increases GFR in humans
[47, 48], usually in association with a rise in filtration fraction.
In our studies [49], oral hydrocortisone administration pro-
duced substantial increases in GFR (inulin clearance) but effec-
tive renal plasma flow (PAH clearance) was unchanged (assum-
ing constant PAH extraction) and filtration fraction rose. Renal
blood flow decreased because of a fall in hematocrit (presum-
ably a consequence of plasma volume expansion), and renal
vascular resistance increased. Whether or how these alterations
in renal function contribute to the rise in blood pressure is not
Fig. 2. Effects of cortisol infusion (6—8 mglhr) on systolic blood pres-
sure, plasma potassium, plasma glucose, urinary sodium excretion,
renin concentration, and renin substrate in volunteer subjects. (Repro-
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Fig. 4. Pressor responsiveness to phenylephrine (ag/kg/min) in subjects
before and after oral hydrocortisone treatment, showing increased
systolic, diastolic, and mean arterial pressure responses on hydrocor-
tisone, with a greater fall in pulse rate. The dose infused is shown on
the horizontal axis.
noted in erythrocytes of patients with Cushing's syndrome [58].
These findings indicate an increased maximal activity of the
sodium-potassium pump in patients with glucocorticoid excess.
Binding sites for ouabain are increased in erythrocytes of
glucocorticoid-treated patients [59]. Wambach and coworkers
speculated that generalized pump activation could contribute to
the volume redistribution [58].
Mechanisms
The profound physiologic perturbations seen with hydrocor-
tisone could be causal in the elevation of blood pressure, could
be simply associated phenomena, or might be modulators or
amplifiers of a blood pressure-raising action of the steroid. As I
will discuss, we have evidence from studies in sheep that the
blood pressure-raising effects of steroids cannot be explained
simply in terms of their glucocorticoid or mineralocorticoid
activities [25, 60, 61]. These observations have led us to
propose that blood pressure-raising effects of steroids might be
in part separate from their classical glucocorticoid or mm-
eralocorticoid actions, and represent a different class of steroid
hormone activity, which we have termed hypertensinogenic
[25, 60, 61]. The possibility remains that cortisol, a classic
glucocorticoid with some mineralocorticoid activity, might
raise blood pressure through its hypertensinogenic activity.
Whereas in sheep it is possible to separate hypertensinogenic
activity from glucocorticoid or mineralocorticoid activity, in
humans the same hypertensinogenic action occurs at a rate of
infusion at which the classic steroid effects also are seen.
Hypertension in experimental animals
Cortisol, cortisone, and corricosterone
Glucocorticoid hypertension was first studied in the rat given
cortisone [62—64] and cortisol acetate [64, 65]. In contrast to
mineralocorticoid hypertension, which is augmented by dietary
z SBP (mm Hg)
N=6DBP (mm Hg)
z MAP (mm Hg)
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Fig. 3. Pressor responsiveness to angiolensin II (ng/kg/min) in subjects
before and during oral hydrocortisone treatment. The dose infused is
shown on the horizontal axis. There are no significant differences. SBP
refers to systolic blood pressure; DBP, diastolic blood pressure; and
MAP, mean arterial pressure.
known. Exaggerated natriuresis has been reported in Cushing's
syndrome [50, 51] as in other forms of hypertension, and
Birchall et al demonstrated a natriuretic response to saline
loading in a normal individual given cortisone [50].
Pressor responsiveness
Reports of changes in vascular responsiveness in glucocorti-
coid-induced hypertension conflict. Some studies have reported
that glucocorticoid administration increases pressor responses
to noradrenaline and adrenaline in humans [52, 53], but this
finding is not universal [54, 55].
In our studies of pressor responsiveness following oral
hydrocortisone administration, we examined the effects of
angiotensin II and phenylephrine [56]. As Figure 3 shows, there
were no changes in pressor responsiveness to angiotensin II
after we gave oral hydrocortisone, 200 mg daily, for 5 days. In
contrast, hydrocortisone increased pressor responsiveness to
phenylephrine at infusion rates from 0.6 to 2.0 ig/kgImin (Fig.
4), and decreased the threshold for systolic and mean arterial
pressure rises. Whether these changes in pressor responsive-
ness contribute to the hydrocortisone-induced rise in blood
pressure is not clear.
Changes in membrane ion transport
Increases in sodium-potassium-ATPase activity in erythro-
cyte ghosts have been reported in patients with Cushing's
syndrome [57] and in patients treated with ACTH [58]. In-
creases in ouabain-sensitive uptake of rubidium also have been
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sodium supplementation [66, 67], prevented by dietary sodium
restriction [63, 68, 69], and characterized by hypokalemia,
hypernatremia, and urinary sodium retention, hypertension
induced by glucocorticoids is independent of dietary sodium
intake, changes in plasma electrolye concentration, and sodium
retention [65, 70]. Cortisol infused intravenously in sheep in
doses of 480 mg/day increased arterial pressure within 24 hours
[70]; in the dog, however, cortisol lowers blood pressure [711.
Corticosterone is the principal glucocorticoid secreted by the
rat adrenal cortex [72]. Corticosterone possesses approximately
equal mineralocortjcoid and glucocorticoid properties, but in
the rat corticosterone-induced hypertension is predominantly
glucocorticoid in type [73, 74].
Synthetic glucocorticoid steroids
Using 9a-fluorocortisol, many groups have produced hyper-
tension in rats [65, 69, 75, 76] and adrenalectomized dogs [77].
Knowlton and colleagues compared the effects of a number of
cortisol analogues on blood pressure in sodium-restricted adre-
nalectomized rats and found that 9a-chlorocortisol, 9n-fluoro-
cortisol, and 9a-fluoroprednisolone were 5 to 10 times more
potent than cortisol in raising blood pressure [691. In rats,
9a-fluorocortisol-induced hypertension is a glucocorticoid
model rather than a mineralocorticoid form of hypertension. In
sheep, 9a-fluorocortisol produced hypertension at a dose with-
out apparent mineralocorticoid or glucocorticoid effects (0.2
mg/daily); this finding suggests that elevated pressure is medi-
ated by a different mode of steroid activity, a phenomenon that
has been given the designation of hypertensinogenic activity
[781.
Cortisol and corticosterone have mineralocorticoid proper-
ties, but many of the synthetic glucocorticoids, which have little
sodium-retaining effect (triamcinolone, dexamethasone, predni-
sone, methylprednisolone) also induce hypertension in rats
[79]. There are important species differences. Although meth-
ylprednisolone induces hypertension in the rat [80—82], chronic
infusion failed to raise blood pressure in the dog [831 or sheep
[84]. Dexamethasone causes hypertension in the rat [85—87] but
not sheep [70].
Mechanisms
We have reviewed in detail the possible mechanisms of
ACTH-dependent hypertension elsewhere [88]. Today I'd like
to briefly review the major potential factors at play for gluco-
corticoid-related hypertension.
Hemodynamics. Whereas mineralocorticoids cause renal so-
dium retention, glucocorticoids produce a shift from interstitial
to plasma volume compartment. It has been postulated that in
consequence, there is an increase in plasma volume, and hence
cardiac output, leading to vascular autoregulation, and an
increase in total peripheral resistance. In turn, the increase in
peripheral resistance is thought to maintain the elevation in
arterial pressure [891. This hypothesis remains unproven [90]. A
number of studies have demonstrated no change or only slight
increases in plasma or blood volume, extracellular fluid volume,
and cardiac output in steroid-induced hypertension [91—931.
Hormonal changes. The renin-angiotensin system probably
plays little part in the pathogenesis of glucocorticoid-induced
hypertension. Krakoff Ct al reported elevated plasma renin
substrate and PRA in methylprednisolone-induced hyperten-
sion in the rat [801, but in another study, PRA remained at
normal levels despite increased plasma renin substrate in
dexamethasone-induced hypertension in the rat [851. Infusion
of saralasin significantly reduced arterial pressure in rats with
methylprednisolone-induced hypertension, but the reduction
was not sufficient to normalize arterial pressure [80, 941. The
partial agonist action of saralasin might account for these
results [951. Subsequently, it was found that captopril failed to
prevent development of glucocorticoid-induced hypertension
and did not reverse it [81, 96].
Few data are available on central or peripheral adrenergic
activity following glucocorticoid administration. In the rat,
plasma catecholamines are not altered by corticosterone treat-
ment [97], although adrenal and brain medullary phenethanol-
amine-N-methyl transferase (PNMT) is increased by glucocor-
ticoid administration. Methylprednisolone-induced hyperten-
sion in the rat can be partially reversed by PNMT inhibition,
suggesting some role for the sympathetic nervous system in
maintaining the pressure [94]. Methylprednisolone hyperten-
sion can be produced in the ADH-deficient Brattleboro rat to
the same degree as in the normal Wistar rat [98] and is not
reversed by an AVP antagonist [94]. Thus, vasopressin does not
play a major role in this form of hypertension [98].
In-vitro studies show that glucocorticoids affect prostaglan-
din biosynthesis by inhibiting the release of arachidonic acid
from phospholipids [99]. Glucocorticoids might raise blood
pressure via inhibition of phospholipase A2, with reduction in
vasodilator prostanoid activity [100]. Cyclooxygenase inhibi-
tion with indomethacin increases pressor responsiveness to
noradrenaline and angiotensin II in a variety of species [101],
including humans.
Vascular smooth muscle responsiveness. Cortisol potentiates
the pressor effects of adrenaline—but not those of noradren-
aline—in the cat, rabbit, and dog [102, 103]. In-vitro prepara-
tions of arterial smooth muscle show increased responsiveness
to both adrenaline and noradrenaline several minutes after
exposure to cortisone [103—105]. Glucocorticoids might in-
crease responses of vascular smooth muscle to adrenaline and
noradrenaline by inhibiting catechol-o-methyl transferase
(COMT) [105]. Pressor responses to subpressor rates of adren-
aline infusion have been observed in cortisol-treated dogs [106].
Handa et al found that an increased pressor response to
noradrenaline preceded the development of hypertension in
dexamethasone-treated rats [87]. The increased vascular reac-
tivity was abolished by indomethacin administration; these
changes in reactivity might be related to altered prostaglandin
synthesis. Other possible explanations include structural
changes of the vascular wall, electrolyte changes, and alter-
ations in sodium-potassium pump activity and permeability. On
the other hand, a number of studies show that glucocorticoids
have no effect on vascular reactivity [80—82, 1071; the literature
is by no means conclusive.
Changes in membrane ion transport. Glucocorticoids in-
crease renal sodium-potassium ATPase activity [1081, and
dexamethasone also increases sodium-potassium pump activity
in rat arteries [109]. GrUnfeld et al found that hypertension
produced in the rat by the synthetic glucocorticoid agonist RU
26988 was associated with increases in total and ouabain-
sensitive sodium efflux and rubidium efllux [110]. Pretreatment
with a glucocorticoid antagonist prevented the changes in total
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and ouabain-sensitive sodium efflux, largely reversed the hy-
pertension, and partially reversed the changes in rubidium
efflux. Whether these observations have any bearing on the
cause of steroid-induced hypertension is unknown.
A "hypertensinogenic" action. The concept of a "hyperten-
sinogenic" class of steroid hormone action, separate from
mineralocorticoid or glucocorticoid actions of steroid hormones
in raising blood pressure, is based on studies in sheep [25, 60,
61, 70, 78, 88, 111]. First, the hypertension produced by ACTH
administration in conscious sheep could not be reproduced by
infusion of the major ovine mineralocorticoid or glucocorticoid
hormones (cortisol, 11 -deoxycortisol, deoxycorticosterone,
corticosterone, and aldosterone) either alone or in combination,
at rates that reproduce blood concentrations of steroid seen
with ACTH administration, although all the metabolic effects
were seen. Following the addition to this combined steroid
infusion of 17a20a hydroxyprogesterone (a steroid isolated
from adrenal vein blood under conditions of ACTH administra-
tion), the effects on blood pressure were identical to those seen
with ACTH. This steroid showed little or no affinity for either
type-I (mineralocorticoid) or type-Il (glucocorticoid) receptors.
The second line of evidence came from the studies on 9a
fluorocortisol in sheep to which I have already alluded [78]; 9a
fluorocortisol raised blood pressure at an infusion rate that had
no in-vivo mineralocorticoid or glucocorticoid effects. At higher
rates of infusion, mineralocorticoid effects were seen, but
infusion of aldosterone and cortisol (at equivalent rates based
on receptor affinity) reproduced the metabolic effects of 9a
fluorocortisol without the hypertension.
The third line of evidence came from extensive studies in
which naturally occurring and synthetic steroids were infused,
and detailed structure-activity studies undertaken. No simple
relationship was found between the blood pressure-raising
effects of steroids (hypertensinogenic activity) and their in-vivo
glucocorticoid activity (assessed by changes in blood glucose
and urine volume) or mineralocorticoid activity (assessed by
changes in urinary sodium excretion). Although all glucocorti-
coids increase plasma glucose and urine volume, some raise
blood pressure with associated mineralocorticoid activity (for
example, cortisol), whereas others are hypertensive without
mineralocorticoid activity (such as cortivazol), or they have
little effect on blood pressure (for example, dexamethasone).
These and other studies have led to the hypothesis that
steroid hormones raise blood pressure by a "hypertensinogen-
ic" action distinct from their classical mineralocorticoid or
glucocorticoid actions [1111. We have proposed that to produce
hypertension a steroid must bind to a putative "hypertensino-
genic" receptor, probably located in the central nervous system
[25]. Elucidation of the "hypertensinogenic" mechanism will
require separation of effects primarily responsible for the rise in
blood pressure from those steroid-dependent effects that may
modify or amplify the rise in pressure. We have proposed that
these latter effects are due to occupancy of classical glucocor-
ticoid and mineralocorticoid receptors.
Treatment
Withdrawal or reduction of the steroid dose obviously is the
best method of treatment of glucocorticoid-induced hyperten-
sion. Conventional antihypertensive therapy is effective in most
cases. Future approaches will involve development of steroids
that are antiinflammatory without having hypertensive activity
(one of the aims of steroid chemists since cortisone was first
synthesized and used).
The Roussell compound RU486 is a potent progesterone and
glucocorticoid antagonist. In humans this compound [17/3-
hydroxy-l l-(4-dimethylaminophenyl)-17a-(prop- l-ynyl)-estra-4,
9—dien-3-one] antagonizes the negative pituitary feedback of
both the nocturnal endogenous cortisol rise and exogenous
dexamethasone [112]. It has been used in Cushing's syndrome,
in which it was effective in reversing clinical features including
the hypertension [1131.
Questions and answers
DR. JOHN T. HARRINGTON (Chief, Department of Medicine,
Newton- Wellesley Hospital, Newton, Massachusetts, USA):
How do you account for the difference between the low
incidence of hypertension in patients receiving exogenous
glucorticoids (16%) versus that in patients with Cushing's
syndrome (80%)?
DR. WHITWORTH: The difference might reflect differences in
the steroids responsible. In Cushing's disease, other steroids as
well as cortisol are elevated and may contribute to the hyper-
tension. These include deoxycortisone, 18 hydroxy-deoxy-
corticosterone, and corticosterone [1141. The lower incidence
of hypertension with exogenous steroid also might reflect the
fact that these patients have a reduced propensity to retain
sodium [24].
DR. Ross R. BAILEY (Department of Nephrology, Christ-
church Hospital, Christchurch, New Zealand): As you pointed
out, there is a high incidence of hypertension in patients with
Cushing's syndrome, both idiopathic and iatrogenic. But when
these patients enter a biochemical remission of their Cushing's
syndrome, how many remain hypertensive? I use the analogy of
Conn's syndrome, in which not all patients treated successfully
become normotensive.
DR. WHITWORTH: Treatment of Cushing's disease is still not
entirely satisfactory. When bilateral adrenalectomy was used,
almost all patients were cured [115], but they required perma-
nent steroid replacement and they were at risk of developing
Nelson's syndrome. When subtotal adrenalectomy was used,
hypertension was corrected in only 60% [116]. In a series of 13
hypertensive patients undergoing transsphenoidal hypophy-
sectomy, blood pressure fell in 11(85%), and in 3 of 13 (23%)
diastolic pressure remained greater than 100 mm Hg [117].
Selective excision of pituitary adenomata by the transsphenoi-
dal approach currently is regarded as the treatment of choice
[118]. Certainly not every patient who has a biochemical
remission becomes normotensive, particularly if the disease is
longstanding. Presumably this situation is analogous to other
cases of secondary hypertension in which correction of the
underlying lesion does not invariably cure the hypertension,
and presumably the mechanisms are similar.
DR. PHILIP HILTON (Senior Lecturer, St. Thomas Hospital,
London, England): What is the role of cardiac output in
glucocorticoid hypotension? Can the blood pressure go up
without a rise in cardiac output?
DR. WHITWORTH: Our studies indicate that the blood pres-
sure rise seen with ACTH and hydrocortisone administration in
humans is associated with an increase in cardiac output [37]. In
Cushing's syndrome, cardiac output is elevated in some but not
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all patients [119, 1201. Whether this rise in cardiac output is
essential for the rise in blood pressure in humans has not been
addressed. In ACTH-induced hypertension in sheep, the rise in
pressure usually is due to a rise in cardiac output, but if this rise
in output is prevented by beta blockade with acebutolol, the
blood pressure increases to the same extent, in association with
a rise in resistance [121]. Thus the usual hemodynamic pattern
can be modified without preventing the development of the
hypertension, suggesting that the rise in output is not causal.
DR. MICHAEL J. D. CASSIDY (Consultant Nephrologist,
Groote Schuur Hospital, Cape Town, South Africa): With
regard to exogenous administration of corticosteroids and treat-
ment of subsequent hypertension, you didn't mention alternate-
day steroid administration. We all know that many side effects
of steroids can be reduced by an alternate-day steroid regime.
Would you comment on the effect of this regimen on hyperten-
sion?
DR. WI-IITWORTH: Some reports indicate that conversion
from daily to alternate-day steroids will reduce blood pressure
[21, 122]. Comparison of low- and high-dose steroid protocols in
renal allograft recipients also shows less hypertension with the
lower dose [123], although the literature on this point is incon-
clusive.
DR. PRASAD MENON (Kuala Lumpur, Malaysia): What role
do glucocorticoids play in stress-related hypertension?
DR. WHITWORTH: The question of stress-related hyperten-
sion is an interesting one. Certainly experimental and clinical
data support the notion that stress might be a factor in the
genesis of hypertension [124], and we have speculated on a
possible link among ACTH, stress, and hypertension [125].
Recently we demonstrated that constant infusion of ACTH at
rates of less than 1 ig/kgfday can raise blood pressure in
humans, and at this rate plasma concentrations of ACTH (but
not of cortisol) are within the physiologic range [1261. Other
workers have shown that biofeedback-assisted relaxation train-
ing in hypertensive patients reduces both blood pressure and
urinary cortisol levels [127], so it is tempting to speculate that a
link might exist.
DR. DUSIT LUMLERTGUL (Chief ofNephrology, Chiang Mai
University, Chiang Mai, Thailand): Is increased atrial natri-
uretic peptide related to the phenomenon of mineralocorticoid
escape?
DR. WHITWORTH: The role of ANP in mineralocorticoid
escape is unclear. My own view is that it is not the primary
factor. In our studies of ACTH and hydrocortisone administra-
tion in humans, we could dissociate the time course of the two
events. Atrial natriuretic peptide is elevated within 24 hours,
days before escape occurs. On the other hand, ANP is known to
suppress both aldosterone and renin secretion in vivo [128], and
it is interesting to speculate that ANP might contribute to the
suppression of aldosterone and renin concentrations that occurs
with both ACTH and hydrocortisone administration 137, 39].
DR. GAVIN BECKER (Department of Nephrology, Royal
Melbourne Hospital, Melbourne, Australia): What are the
prospects for the development of steroids with antiinflamma-
tory actions but without deleterious—that is, hypertensive—
effects on the cardiovascular system?
DR. WHITWORTH: This goal has been the aim of steroid
chemists since synthetic steroids were introduced into clinical
practice by Hench. Millions of patients around the world are
treated with these drugs each year, so clearly the development
of steroids with few side effects would be useful. In an effort to
reduce the cardiovascular morbidity and mortality of steroid
treatment, chemists have concentrated on minimizing the mm-
eralocorticoid effects of salt and water retention. As the blood
pressure-raising effects of steroids can be divorced, at least in
part, from their mineralocorticoid and glucocorticoid effects
(even though these may amplify the hypertension), then a better
approach might be to screen for "hypertensinogenic" activity.
The use of computer-based modeling with development of more
precise steroid structure-activity relationships holds some
promise for the development of new and safer steroids.
DR. HARRINGTON: DoesRU 486 block the action of what you
have termed "hypertensinogenic" steroids?
DR. WHITWORTH: Preliminary studies have been done in
sheep. This investigational compound does not block ACTH-
induced hypertension, but at the doses used, it was not very
effective in blocking glucocorticoid-type effects such as the rise
in blood glucose.
DR. MARTIN WALTER (Royal Melbourne Hospital): Can you
explain why patients with ectopic ACTH secretion often have
marked metabolic changes without much change in their blood
pressure?
DR. WHITWORTH: A number of factors are possible. The time
course of the disease tends to be short, so that there might not
be time for the pressure rise to develop fully. Many of the
patients have underlying malignancy and may be ill and cachec-
tic so that they cannot mount a large blood pressure response.
There may be a different pattern of steroid production.
In the context of ectopic ACTH, it is important to remember
that Cushing's syndrome with an adrenal tumor is not always
due to steroid overproduction. Pheochromocytoma can pro-
duce ACTH. Thus it is important to measure urinary catechol-
amines in patients presenting with Cushing's syndrome and an
adrenal mass [129] to avoid the potentially disastrous conse-
quences of operating on an undiagnosed pheochromocytoma.
DR. WALTER: Would you please comment on dexametha-
sone-suppressible hypertension?
Da. WHITWORTH: Dexamethasone-suppressible hyperten-
sion is an autosomal dominant condition characterized by
hypertension and hypokalemia [130—132], although the latter is
not invariable [133]. Aldosterone secretion is increased, plasma
volume is expanded, plasma renin is suppressed, and cortisol is
normal. The abnormalities are reversed by low doses of syn-
thetic glucocorticoids, and aldosterone is profoundly sup-
pressed. New et al could not reproduce the hypertension in a
dexamethasone-suppressed patient by infusing aldosterone (or
DOC or 18-OH-DOC) [134]; thus the elevated aldosterone
secretion probably is not the cause of the hypertension. Admin-
istration of ACTH did reproduce the hypertension, and with
continuing ACTH administration, the increase in aldosterone
secretion was maintained. The steroids or steroids responsible
for the blood pressure elevation are not known.
DR. NAPIER M. THOMSON (Department of Nephrology,
Prince Henry's Hospital, Melbourne): Are receptor numbers
altered in Cushing's syndrome?
Da. WHITWORTH: Glucocorticoid receptors are found in
virtually all mammalian tissues. The number of receptors in
lymphocytes from patients with both Cushing's syndrome and
Addison's disease is normal [135], but receptor number is low in
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anorexia nervosa [1361 and depression [1371. There also is
evidence in vivo that glucocorticoid administration decreases
lymphocyte glucocorticoid binding sites in humans [1381.
DR. BRIAN HUTCHISON (Renal Physician, Sir Charles
Gairdner Hospital, Perth, Western Australia): Does preexisting
saline depletion or overload modulate the development of
glucocorticoid-induced hypertension?
DR. WHITWORTH: In early experimental studies, glucocorti-
coid hypertension was distinguished from mineralocorticoid
hypertension by a variety of features, including independence
of sodium status [63, 69]. However, although glucocorticoid
hypertension can develop in the absence of salt loading, it can
be modified by sodium status. Studies of cortisol-induced
hypertension in sheep showed that acute sodium depletion
blunted the cortisol-induced pressure rise [139]. We have
shown in humans that the ACTH-induced rise in pressure is
potentiated by salt loading [140]. In studies done in Glasgow,
the increase in blood pressure was blunted by sodium restric-
tion 1141]. Thus, although sodium is not essential for the rise in
pressure, it is an important modulator of that rise.
DR. K. S. CHUGH (Postgraduate Medical Institute, Chandi-
garh, India): Some of our renal transplant patients who have
been under our observation for more than 10 years have not
developed hypertension even though they have been taking
steroids all along. What is the possible explanation for that?
DR. WHITWORTH: In all the experimental human studies I
have quoted, the blood pressure rises, although there is consid-
erable individual variation. Whether patients taking steroids
become hypertensive depends on whether their pressure rises
to a certain level arbitarily defined as hypertension; this in-
crease in turn depends on individual susceptibility, the level of
starting pressure, and the dose and duration of steroid therapy,
and likely will be influenced by a host of other factors, such as
diet, functional renal mass, and other drug therapy.
DR. SWANEPOEL (University of Cape Town, Groote Schuur
Hospital): It is said that diabetic patients who are hypertensive
retain sodium because of decreased insulin action on cells. Do
you have any information on steroids and the cellular action of
insulin in patients taking steroids? Also, atrial natriuretic factor
and insulin are antagonistic as far as natriuresis is concerned.
Do you have any data about this interaction in steroid-treated
patients?
DR. WHITWORTH: The effects of oral hydrocortisone, dexa-
methasone, and prednisolone have been compared in normal
volunteers. All three glucocorticoids reduce glucose tolerance
and insulin sensitivity. In one study, hydrocortisone and
dexamethasone caused a reduction in specific insulin binding to
erythrocytes, due to decreased binding affinity, but predniso-
lone did not; the authors concluded that other mechanisms,
such as altered post-receptor events, might play a major role in
the induction of insulin resistance in hypercortisolism in hu-
mans [142]. Whether insulin contributes to other observed
metabolic consequences of glucocorticoid administration—for
example, the hypokalemia—is unresolved.
Certainly insulin has antinatriuretic actions. Insulin stimu-
lates Na-K ATPase [143], whereas ANP has no effects on Na-K
ATPase [144]. I am not aware of studies in vivo of direct
interactions of ANP and insulin, and such interactions have not
been examined in steroid hypertension in humans or animals.
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